# Quince Therapeutics, Inc. (QNCX) — capital_raise/private_placement [completed]
Source: sec.gov · situation sit_1fcd2c069afe5988b555 · public 3459373878293805457 · retrieved 2026-08-19T11:57:23.543Z

## Overview
Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, disease-modifying therapies for serious underserved diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH).

On May 18, 2026, Quince Therapeutics completed a stock-for-stock merger to acquire Orphai Therapeutics, a clinical-stage biotechnology company, bringing LAM-001 (an inhaled formulation of rapamycin) into Quince's pipeline. Concurrent with the acquisition, Quince closed a private placement financing with gross upfront proceeds of $115 million ($103.6 million net after $11.4 million in placement agent and offering expenses) for Series C non-voting convertible preferred stock, with potential for up to an additional $83 million upon exercise of warrants issued to investors and former Orphai stockholders.

## Terms
- Counterparty: Orphai Therapeutics · Deal value: $115.0M · Consideration: stock

## Key dates
- Completed 2026-05-18

## Timeline
- 2026-08-14 · 8-K (0001193125-26-350568): 8-K - Quince Therapeutics, Inc. — *Quince Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, disease-modifying therapies for serious underserved diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH).* On May 18, 2026, Quince Therapeutics completed a stock-for-stock merger to acquire Orphai Therapeutics, a clinical-stage biotechnology company, bringing LAM-001 (an inhaled formulation of rapamycin) into Quince's pipeline. Concurrent with the acquisition, Quince closed a private placement financing with gross upfront proceeds of $115 million ($103.6 million net after $11.4 million in placement agent and offering expenses) for Series C non-voting convertible preferred stock, with potential for up to an additional $83 million upon exercise of warrants issued to investors and former Orphai stockholders.
  https://www.sec.gov/Archives/edgar/data/1662774/0001193125-26-350568.txt

## Citations
- 0001193125-26-350568 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526350568